{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm", "query": { "condition": "Malignant Neoplasm" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 6487, "total_pages": 649, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-11T01:30:54.925Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02092948", "title": "Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Pancreatic Cancer", "Bladder Cancer" ], "interventions": [ { "name": "[124I] PSCA-Minibody PET/CT imaging of the whole body", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2013-08-22", "completion_date": "2017-01-06", "has_results": false, "last_update_posted_date": "2020-07-27", "last_synced_at": "2026-06-11T01:30:54.925Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02092948" }, { "nct_id": "NCT05791448", "title": "AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cholangiocarcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Neoplasm in the Liver", "Refractory Malignant Solid Neoplasm", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "RNA Transcription Modulator AU-409", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-03-29", "completion_date": "2028-03-29", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-11T01:30:54.925Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05791448" }, { "nct_id": "NCT00075608", "title": "2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Plasma Cell Neoplasm" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "melphalan", "type": "DRUG" }, { "name": "autologous stem cell transplantation", "type": "PROCEDURE" }, { "name": "stem cell infusion", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2001-08", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2017-01-27", "last_synced_at": "2026-06-11T01:30:54.925Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00075608" }, { "nct_id": "NCT02648490", "title": "An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumour" ], "interventions": [ { "name": "HLX07", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "diphenhydramine", "type": "DRUG" }, { "name": "5-HT3 inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Henlix, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2016-09", "completion_date": "2019-06-28", "has_results": false, "last_update_posted_date": "2019-07-30", "last_synced_at": "2026-06-11T01:30:54.925Z", "location_count": 1, "location_summary": "Fremont, California", "locations": [ { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02648490" }, { "nct_id": "NCT05006482", "title": "Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Comprehensive Geriatric Assessment", "type": "OTHER" }, { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Exercise Intervention", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Tailored Intervention", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 668, "start_date": "2023-03-21", "completion_date": "2027-09-17", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-06-11T01:30:54.925Z", "location_count": 45, "location_summary": "Tuscaloosa, Alabama • Fremont, California • San Francisco, California + 34 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Fremont", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT05006482" }, { "nct_id": "NCT00104923", "title": "Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "fenretinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Cancer Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 29, "start_date": "2005-02", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-07-19", "last_synced_at": "2026-06-11T01:30:54.925Z", "location_count": 4, "location_summary": "Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104923" }, { "nct_id": "NCT00424242", "title": "Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Metastatic Cancer", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Precancerous Condition", "Secondary Myelofibrosis", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 15, "start_date": "2007-01", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2021-09-08", "last_synced_at": "2026-06-11T01:30:54.925Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00424242" }, { "nct_id": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2 Low", "SYD-985", "SYD985", "Vic-trastuzumab Duocarmazine", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic", "HER2 Low Breast Cancer", "GastroEsophageal Cancer", "Gastroesophageal Adenocarcinoma", "Endometrium Tumor", "Ovarian Cancer", "Ovarian Carcinoma", "HER2-positive Gastric Cancer", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2 Low HR Positive", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Triple Negative Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Bladder Cancer" ], "interventions": [ { "name": "Vic-trastuzumab duocarmazine (SYD985) + paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-07-28", "completion_date": "2021-11-17", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-06-11T01:30:54.925Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04602117" }, { "nct_id": "NCT00611468", "title": "Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumor" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accelerated Community Oncology Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2006-06", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2011-08-22", "last_synced_at": "2026-06-11T01:30:54.925Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00611468" }, { "nct_id": "NCT04234568", "title": "Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Digestive System Neuroendocrine Neoplasm", "Metastatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Triapine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2020-07-20", "completion_date": "2027-03-13", "has_results": true, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-11T01:30:54.925Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04234568" } ] }